512 — Grand Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$15.09bn
- HK$19.44bn
- HK$12.28bn
Brief: Grand Pharmaceutical Says Novasight Approved By NMPA For Commercialization In China
Brief: Grand Pharmaceutical's Global Innovative RDC Drug I-11 Obtained Implied Approval From NMPA
Brief: Grand Pharmaceutical's Global Innovative Hormone Nanosuspension Eye Drops Submitted NDA To FDA
Brief: Grand Pharmaceutical Group Says Phase II Clinical Research For Stc3141 Was Accepted By NMPA
Brief: Grand Pharmaceutical Says Phase II Clinical Trial For Ophthalmic Drug Gpn00136 Got Implied Approval From NMPA
Brief: Grand Pharmaceutical Says Phase III Clinical Trial Application Of GPN00833 Got Implied NMPA Approval
Brief: Grand Pharmaceutical Says TLX101 Got Implied NMPA Approval To Conduct Phase I Clinical Study
Brief: Grand Pharmaceutical Says Investigational New Drug (Ind) Application Of Apad Approved By NMPA
Brief: Grand Pharmaceutical Group Posts FY Revenue HK$9,562.29 Mln VS Hk$8,597.98 Mln
Brief: Grand Pharmaceutical Says Unit To Subscribe For 29.6 Mln Sirtex Holdco Shares
Brief: Assicurazioni Generali SpA's Long Position In Grand Pharmaceutical Rises To 5.05% - Filing
Brief: Grand Pharmaceutical Says Drug Achieved Clinical Study Endpoint Of Phase Ib Trial In China
Brief: Grand Pharmaceutical Says Clinical Trial Application For Tlx591-Cdx Approved
Brief: Grand Pharmaceutical Says Clinical Trial Application In China For Global Innovative Radionuclide-Drug Conjugate Approved
Brief: Grand Pharmaceutical Announces Profit Alert for Six Months
Brief: Grand Pharmaceutical Sees Consol Net Profit Attributable Decrease For Six Months
Brief: Grand Pharmaceutical Clinical Trial Applications Radionuclide-Drug Conjugates Tlx591-Cdx And Tlx250-Cdx Accepted By Nmpa
Brief: Grand Pharmaceutical Says Co, XELTIS AG Entered Strategic Cooperation Agreement
Brief: Grand Pharmaceutical's Unit And Sirtex Medical Entered Into Distribution Agreement